Notice: This company has been marked as potentially delisted and may not be actively trading. Lionheart Acquisition Co. II (LCAP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends LCAP vs. NVCT, MGNX, EPRX, ACRS, SERA, CORBF, ALEC, FTLF, ZNTL, and AMWLShould you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Nuvectis Pharma (NVCT), MacroGenics (MGNX), Eupraxia Pharmaceuticals (EPRX), Aclaris Therapeutics (ACRS), Sera Prognostics (SERA), Global Cord Blood (CORBF), Alector (ALEC), FitLife Brands (FTLF), Zentalis Pharmaceuticals (ZNTL), and American Well (AMWL). These companies are all part of the "medical" sector. Lionheart Acquisition Co. II vs. Nuvectis Pharma MacroGenics Eupraxia Pharmaceuticals Aclaris Therapeutics Sera Prognostics Global Cord Blood Alector FitLife Brands Zentalis Pharmaceuticals American Well Nuvectis Pharma (NASDAQ:NVCT) and Lionheart Acquisition Co. II (NASDAQ:LCAP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment. Does the MarketBeat Community believe in NVCT or LCAP? Nuvectis Pharma received 10 more outperform votes than Lionheart Acquisition Co. II when rated by MarketBeat users. CompanyUnderperformOutperformNuvectis PharmaOutperform Votes1090.91% Underperform Votes19.09%Lionheart Acquisition Co. IIN/AN/A Which has better valuation and earnings, NVCT or LCAP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$22.26M-$1.11-6.97Lionheart Acquisition Co. IIN/AN/A$3.21MN/AN/A Is NVCT or LCAP more profitable? Lionheart Acquisition Co. II's return on equity of -44.30% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -155.80% -104.02% Lionheart Acquisition Co. II N/A -44.30%1.39% Does the media refer more to NVCT or LCAP? In the previous week, Nuvectis Pharma had 2 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 2 mentions for Nuvectis Pharma and 0 mentions for Lionheart Acquisition Co. II. Lionheart Acquisition Co. II's average media sentiment score of 0.00 beat Nuvectis Pharma's score of -0.38 indicating that Lionheart Acquisition Co. II is being referred to more favorably in the news media. Company Overall Sentiment Nuvectis Pharma Neutral Lionheart Acquisition Co. II Neutral Do analysts prefer NVCT or LCAP? Nuvectis Pharma currently has a consensus target price of $11.00, suggesting a potential upside of 42.12%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Nuvectis Pharma is more favorable than Lionheart Acquisition Co. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Lionheart Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, NVCT or LCAP? Nuvectis Pharma has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Lionheart Acquisition Co. II has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Do institutionals & insiders hold more shares of NVCT or LCAP? 96.8% of Nuvectis Pharma shares are owned by institutional investors. 35.8% of Nuvectis Pharma shares are owned by insiders. Comparatively, 19.4% of Lionheart Acquisition Co. II shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryNuvectis Pharma beats Lionheart Acquisition Co. II on 8 of the 12 factors compared between the two stocks. Remove Ads Get Lionheart Acquisition Co. II News Delivered to You Automatically Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LCAP vs. The Competition Export to ExcelMetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.66M$145.34M$5.64B$8.08BDividend YieldN/AN/A4.89%4.04%P/E RatioN/A0.8523.7319.00Price / SalesN/A32.09381.75120.61Price / Cash20.6411.7038.0534.64Price / Book-0.624.086.904.26Net Income$3.21M$1.30M$3.18B$247.00M Lionheart Acquisition Co. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LCAPLionheart Acquisition Co. IIN/A$1.77-2.2%N/A+94.4%$32.66MN/A0.003Gap DownNVCTNuvectis Pharma3.1374 of 5 stars$6.14-8.2%$11.00+79.2%-27.8%$143.63MN/A-5.298Short Interest ↓MGNXMacroGenics4.0914 of 5 stars$2.28-7.3%$7.63+234.4%-86.5%$143.10M$139.77M-1.44430EPRXEupraxia Pharmaceuticals1.7984 of 5 stars$3.94-2.7%$10.50+166.5%N/A$140.45MN/A-5.4729Gap DownACRSAclaris Therapeutics2.9722 of 5 stars$1.96-1.5%$11.00+461.2%+27.9%$140.01M$27.08M-3.77100SERASera Prognostics0.2955 of 5 stars$4.14-2.4%N/A-54.3%$139.82M$94,000.00-4.18120Upcoming EarningsCORBFGlobal Cord BloodN/A$1.15+43.8%N/AN/A$139.78M$196.12M0.001,200Gap DownALECAlector3.4573 of 5 stars$1.41-14.0%$3.75+166.0%-78.2%$139.71M$100.56M-0.83270High Trading VolumeFTLFFitLife Brands4.6371 of 5 stars$15.10+0.6%$20.00+32.5%+27.4%$139.07M$62.76M17.8720ZNTLZentalis Pharmaceuticals2.3807 of 5 stars$1.92-7.2%$8.24+329.4%-86.8%$136.83M$40.56M-0.77160AMWLAmerican Well3.714 of 5 stars$8.74-12.2%$11.90+36.2%-59.3%$136.43M$254.36M-0.621,104Negative NewsGap Down Remove Ads Related Companies and Tools Related Companies NVCT Alternatives MGNX Alternatives EPRX Alternatives ACRS Alternatives SERA Alternatives CORBF Alternatives ALEC Alternatives FTLF Alternatives ZNTL Alternatives AMWL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LCAP) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredWarning: What they're not telling you about these recent selloffsIn light of massive recent selloffs... our senior analyst Dan Ferris has issued a new warning for the American...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lionheart Acquisition Co. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Lionheart Acquisition Co. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
